Staggering Results Show HIV-Transmission Reduced 100% with Twice-Yearly Lenacapavir Injection
Clinical trials for the drug Lenacapavir have demonstrated near-perfect efficacy in preventing HIV transmission through twice-yearly injections. The drug offers a significant improvement in adherence and social discretion compared to daily oral prevention pills.
Why it matters
This breakthrough could drastically reduce global HIV infection rates by overcoming the adherence challenges associated with daily medication regimens.
A 2-stage trial testing a new and acclaimed HIV-prevention drug has shown almost unthinkable results of no new infections among a sample size of 3,200 participants.
The article reports on clinical trial results and medical advancements without overt political or ideological framing.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in